Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18443894 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | February 2024 | September 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18423006 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | January 2024 | March 2026 | Allow | 25 | 2 | 1 | No | No |
| 18574764 | EPSTEIN-BARR VIRUS (EBV) ANTIGEN COMPOSITES AND DENDRITIC CELL (DC)-BASED VACCINE, AND USE THEREOF | December 2023 | August 2025 | Allow | 19 | 3 | 0 | Yes | No |
| 18389914 | ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | December 2023 | March 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18512432 | Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof | November 2023 | November 2025 | Allow | 24 | 2 | 0 | No | No |
| 18500492 | MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS | November 2023 | October 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18495541 | COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGS | October 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18495532 | Th1 vaccination priming for active immunotherapy | October 2023 | August 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18466354 | GENETICALLY ENGINEERED GAMMA DELTA T CELL | September 2023 | July 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18450234 | Methods to Expand a T Regulatory Cell Master Cell Bank | August 2023 | June 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18448870 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | August 2023 | January 2025 | Allow | 17 | 2 | 0 | No | No |
| 18230449 | SYSTEM AND METHOD OF PREPARING AND STORING ACTIVATED MATURE DENDRITIC CELLS | August 2023 | April 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18218943 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF | July 2023 | February 2024 | Allow | 8 | 2 | 1 | Yes | No |
| 18342897 | IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION | June 2023 | May 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18317199 | COMPOSITION FOR CULTURING REGULATORY T CELLS AND USE THEREOF | May 2023 | October 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18299922 | VIRUS SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING VIRAL INFECTIONS | April 2023 | September 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18298129 | CELLULAR POPULATIONS AND USES THEREOF | April 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18298263 | INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18295965 | MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS | April 2023 | October 2024 | Allow | 19 | 1 | 1 | No | No |
| 18168114 | REGULATORY T CELLS GENETICALLY MODIFIED FOR THE LYMPHOTOXIN ALPHA GENE AND USES THEREOF | February 2023 | February 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18158146 | GAMMADELTA T CELL EXPANSION PROCEDURE | January 2023 | April 2025 | Abandon | 27 | 2 | 1 | No | No |
| 17782336 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BEHCET'S DISEASE AND RHEUMATOID ARTHRITIS, CONTAINING PEPTIDE OR MIXTURE THEREOF AS ACTIVE INGREDIENT | December 2022 | November 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 18067484 | Multivalent and Multispecific 41BB-Binding Proteins | December 2022 | August 2024 | Allow | 20 | 0 | 1 | No | No |
| 18062601 | ANTI-HUMAN GRP94 ANTIBODIES AND USES | December 2022 | July 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17928600 | VACCINE FORMULATIONS | November 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18048233 | USE OF TRANS-SIGNALING APPROACH IN CHIMERIC ANTIGEN RECEPTORS | October 2022 | January 2025 | Allow | 27 | 2 | 1 | No | No |
| 17968410 | OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF | October 2022 | June 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17995872 | INFLUENZA VIRUS SURFACE PROTEIN-DERIVED RECOMBINANT HEMAGGLUTININ PROTEIN FORMING TRIMER, AND USE THEREOF | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17995733 | SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17938536 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | October 2022 | February 2024 | Abandon | 17 | 1 | 1 | No | No |
| 17995008 | A UNIVERSAL ADOPTIVE IMMUNOTHERAPY APPROACH TO TREAT COVID-19 AND FUTURE EMERGING INFECTIOUS DISEASES | September 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17915986 | SARS-COV-2 VACCINES FOR POPULATION-SCALE IMMUNITY | September 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17905962 | A LIVE ATTENUATED MEASLES VIRUS VECTORED VACCINE FOR SARS-COV-2 | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17940967 | CORONAVIRUS VACCINE | September 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17893579 | REGULATORY T CELL EPITOPES | August 2022 | January 2025 | Allow | 29 | 2 | 2 | Yes | No |
| 17801391 | KRAS EPITOPES AND ANTIBODIES | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17904053 | CORONA VIRUS VACCINE | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17871680 | NF-KB SIGNALING PATHWAY-MANIPULATED DENDRITIC CELLS | July 2022 | July 2024 | Allow | 24 | 1 | 1 | No | No |
| 17863558 | MATERIALS AND METHODS FOR MODIFYING THE ACTIVITY OF T CELLS | July 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17850825 | Compositions and Methods for Inhibiting T Cell Exhaustion | June 2022 | July 2025 | Allow | 36 | 3 | 1 | Yes | No |
| 17841447 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | June 2022 | May 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17839397 | Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity | June 2022 | May 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17836176 | COMPOSITIONS AND METHODS FOR IN VITRO CULTIVATION AND/OR EXPANSION OF REGULATORY T CELLS | June 2022 | February 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17832214 | BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF | June 2022 | July 2024 | Abandon | 26 | 2 | 1 | Yes | No |
| 17827957 | INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17824650 | TRANSGENIC T CELL AND CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND RELATED METHODS | May 2022 | May 2025 | Allow | 35 | 0 | 0 | No | No |
| 17748831 | Methods and compositions for liquidation of tumors | May 2022 | January 2026 | Abandon | 44 | 4 | 0 | No | No |
| 17745459 | MODULATION OF IMMUNE RESPONSE USING BTLA AGONIST ANTIBODIES | May 2022 | July 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17663558 | PI16 ANTIBODIES | May 2022 | October 2023 | Allow | 17 | 0 | 0 | No | No |
| 17743181 | COMPOSITION FOR CULTURING REGULATORY T CELLS AND USE THEREOF | May 2022 | April 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17735146 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT | May 2022 | June 2024 | Allow | 26 | 2 | 0 | No | No |
| 17727107 | METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENEIC T CELLS | April 2022 | October 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17721577 | INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY | April 2022 | January 2023 | Allow | 9 | 1 | 1 | No | No |
| 17709979 | METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD | March 2022 | November 2022 | Allow | 7 | 0 | 0 | Yes | No |
| 17765394 | PRODUCTION OF ANTI-VIRAL MONOCLONAL ANTIBODIES BY HYDRODYNAMIC-BASED TRANSFECTION | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17762836 | COMPOSITION FOR CULTURING PERIPHERAL BLOOD MONOCYTE-DERIVED REGULATORY T CELL AND REGULATORY T CELL CULTURING METHOD USING SAME | March 2022 | August 2025 | Allow | 41 | 1 | 1 | No | No |
| 17701535 | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | March 2022 | December 2024 | Allow | 33 | 4 | 1 | No | No |
| 17698608 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | March 2022 | October 2024 | Abandon | 30 | 1 | 1 | Yes | No |
| 17693717 | VIRUS SPECIFIC T-CELLS AND METHODS OF TREATING AND PREVENTING VIRAL INFECTIONS | March 2022 | July 2023 | Abandon | 16 | 2 | 1 | No | No |
| 17681616 | IMMUNOLOGICAL BIOMARKER FOR PREDICTING CLINICAL EFFECT OF CANCER | February 2022 | October 2024 | Allow | 32 | 2 | 1 | No | No |
| 17585815 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | January 2022 | June 2024 | Allow | 28 | 2 | 0 | No | No |
| 17585377 | STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF | January 2022 | October 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17583117 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | January 2022 | December 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17576321 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF | January 2022 | October 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17454108 | AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) | November 2021 | February 2024 | Allow | 27 | 1 | 0 | No | No |
| 17521113 | EX VIVO GENERATION OF GAMMA DELTA FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17514136 | LYMPH NODE AS A SITE FOR TRANSPLANTATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES AND ORGANS | October 2021 | October 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17510902 | METHOD FOR LARGE-SCALE PRODUCTION OF ALLOSPECIFIC TYPE 1 REGULATORY TREGS (TR1) STABLE IN THE PRESENCE OF PROINFLAMMATORY CYTOKINES WITH THERAPEUTIC POTENTIAL IN TRANSPLANTATION | October 2021 | June 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17507002 | METHOD FOR OBTAINING IMMUNO-SUPPRESSIVE DENDRITIC CELLS | October 2021 | August 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17437423 | ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY DRUG CONJUGATES COMPRISING SAME | September 2021 | May 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17404538 | METHODS FOR ELICITING SELECTIVE HUMORAL RESPONSES | August 2021 | December 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17444765 | USE OF BMMFI REP PROTEIN AS A BIOMARKER FOR PROSTATE CANCER | August 2021 | September 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17427655 | NOVEL ANTI-IFNAR1 ANTIBODIES | August 2021 | November 2025 | Allow | 52 | 2 | 1 | No | No |
| 17426695 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | July 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17385834 | ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER | July 2021 | June 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17376314 | HUMANIZED ANTIBODIES WITH INCREASED STABILITY | July 2021 | October 2024 | Allow | 39 | 2 | 1 | No | No |
| 17374224 | NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1 | July 2021 | November 2023 | Allow | 28 | 2 | 0 | No | No |
| 17422113 | FUSION PROTEIN WITH IMMUNOSUPPRESSIVE ACTIVITY | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17371589 | METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS | July 2021 | August 2024 | Allow | 38 | 3 | 0 | Yes | No |
| 17422095 | MUL TISPECIFIC PROCHEMOKINE THERAPEUTIC PROTEINS (PARK) AND METHOD OF MAKING AND USING THEREOF | July 2021 | April 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17421705 | LILRB3-BINDING MOLECULES AND USES THEREFOR | July 2021 | May 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17421476 | GALECTIN-7-SPECIFIC MONOVALENT ANTIBODIES AND USES THEREOF | July 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17420365 | TREATMENT OF SJOGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS | July 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17360870 | IMMUNOPOTENTIATING OR ANTICANCER ACTIVITY-AUGMENTING COMPOSITION COMPRISING MAL-EXPRESSED STEM CELL LIKE MEMORY T CELL AS ACTIVE INGREDIENT | June 2021 | December 2022 | Abandon | 18 | 1 | 1 | No | No |
| 17417480 | MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF | June 2021 | January 2026 | Allow | 55 | 3 | 1 | No | No |
| 17355532 | Anti-CD3 Antibodies, Bispecific Antigen-Binding Molecules that Bind CD3 and CD20, and Uses Thereof | June 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17311587 | IDENTIFICATION OF GUT BACTERIA THAT PROMOTE AN ANTI-TUMOR RESPONSE TO IMMUNOTHERAPY | June 2021 | September 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17338597 | ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | June 2021 | September 2023 | Allow | 27 | 1 | 0 | No | No |
| 17338566 | ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | June 2021 | September 2023 | Allow | 27 | 1 | 0 | No | No |
| 17329859 | TGFBeta Antibodies, Methods and Uses | May 2021 | January 2025 | Allow | 43 | 1 | 1 | No | No |
| 17324188 | COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION | May 2021 | July 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17317333 | METHODS AND KITS FOR TREATING PAIN | May 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17236534 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF | April 2021 | February 2024 | Allow | 34 | 2 | 1 | No | No |
| 17236463 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF | April 2021 | September 2023 | Allow | 28 | 1 | 0 | No | No |
| 17227642 | ANTIBODIES TO TIGIT | April 2021 | March 2024 | Allow | 35 | 2 | 1 | No | No |
| 17283558 | NOVEL ANTI-SIRPA ANTIBODIES | April 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17217635 | NOVEL RECEPTORS FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | March 2021 | September 2023 | Allow | 30 | 5 | 1 | No | No |
| 17213461 | EX VIVO USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN FOR ENHANCING THE EFFICACY OF ADOPTIVE CELL THERAPY | March 2021 | May 2024 | Allow | 38 | 2 | 1 | Yes | Yes |
| 17214061 | REGULATORY T CELL EPITOPES | March 2021 | October 2023 | Allow | 31 | 1 | 1 | No | No |
| 17301123 | Methods and Compositions for Treating Autoimmune and Inflammatory Conditions | March 2021 | December 2023 | Allow | 32 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JUEDES, AMY E.
With a 12.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JUEDES, AMY E works in Art Unit 1644 and has examined 1,082 patent applications in our dataset. With an allowance rate of 39.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner JUEDES, AMY E's allowance rate of 39.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JUEDES, AMY E receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JUEDES, AMY E is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.8% benefit to allowance rate for applications examined by JUEDES, AMY E. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.8% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.0% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 36.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 35% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 60.9% of appeals filed. This is in the 38% percentile among all examiners. Of these withdrawals, 89.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 79.2% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.4% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.